	US 12,422,441 B2
	Antibodies that bind to natively folded myocilin
Raquel L. Lieberman, Atlanta, GA (US); Shannon E. Hill, Lutz, FL (US); Athena Patterson-Orazem, Gaithersburg, MD (US); Jennifer A. Maynard, Austin, TX (US); Ahlam Qerqez, Austin, TX (US); and Laura Azouz Yuan, Austin, TX (US)
Assigned to Georgia Tech Research Corporation, Atlanta, GA (US)
Appl. No. 17/311,547
Filed by Georgia Tech Research Corporation, Atlanta, GA (US); and Board of Regents, The University of Texas System, Austin, TX (US)
PCT Filed Dec. 9, 2019, PCT No. PCT/US2019/065196 § 371(c)(1), (2) Date Jun. 7, 2021, PCT Pub. No. WO2020/118293, PCT Pub. Date Jun. 11, 2020.
Claims priority of provisional application 62/776,799, filed on Dec. 7, 2018.
Prior Publication US 2022/0026445 A1, Jan. 27, 2022
Int. Cl. G01N 33/68 (2006.01); C07K 16/18 (2006.01)

CPC G01N 33/6893 (2013.01) [C07K 16/18 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); G01N 2800/168 (2013.01)]

18 Claims

1. An antibody or antigen-binding fragment thereof that specifically binds to natively folded myocilin but does not bind to misfolded myocilin;

wherein the antibody comprises:

a HCDR1 domain having the amino acid sequence according to SEQ ID NO:12;

a HCDR2 domain having the amino acid sequence according to SEQ ID NO:13;

a HCDR3 domain having the amino acid sequence FVY;

a LCDR1 domain having the amino acid sequence according to SEQ ID NO:9;

a LCDR2 domain having the amino acid sequence according to SEQ ID NO:10; and

a LCDR3 domain having the amino acid sequence according to SEQ ID NO:11.